CAPTRUST Financial Advisors
ALLO icon

CAPTRUST Financial Advisors’s Allogene Therapeutics ALLO Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$219K Buy
89,938
+36,837
+69% +$73.8K ﹤0.01% 2617
2025
Q4 		$72.7K Buy
53,101
+37,386
+238% +$49.3K ﹤0.01% 2644
2025
Q3 		$19.5K Buy
+15,715
New +$18.7K ﹤0.01% 2605
2022
Q3 		– Sell
-461
Closed -$5K – 2127
2022
Q2 		$5K Sell
461
-749
-62% -$6.65K ﹤0.01% 4055
2022
Q1 		$11K Buy
1,210
+1,192
+6,622% +$12.4K ﹤0.01% 3730
2021
Q4 		$0 Sell
18
-147
-89% -$2.59K ﹤0.01% 4755
2021
Q3 		$4K Hold
165
– – ﹤0.01% 4007
2021
Q2 		$4K Buy
+165
New +$4.71K ﹤0.01% 3927

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return